Display options
Share it on

Cancer. 1990 Aug 15;66(4):627-31. doi: 10.1002/1097-0142(19900815)66:4<627::aid-cncr2820660404>3.0.co;2-0.

Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (PAME) chemotherapy.

Cancer

N Milpied, C Gisselbrecht, J L Harousseau, C Sebban, F Witz, X Troussard, N Gratecos, M Michallet, V LeBlond, G Auzanneau

Affiliations

  1. Department of Hematology, C.H.U. Nantes, France.

PMID: 2386891 DOI: 10.1002/1097-0142(19900815)66:4<627::aid-cncr2820660404>3.0.co;2-0

Abstract

Thirty-nine patients with relapsed acute lymphoblastic leukemia (ALL) and four with primarily refractory ALL were treated with a regimen that included cytarabine 1 gm/m2 (2-hour infusion) twice daily days 1 to 5, mitoxantrone 12mg/m2 daily days 1 to 5, prednisone 0.5 mg/kg daily days 1 to 5, and etoposide 200 mg/m2/day daily days 6 to 8. Of the 43 patients, 30 achieved a complete remission (CR), 28 out of the 39 relapsed patients and two among the four with refractory disease. Five patients died in aplasia. Eight patients were nonresponders. Nonhematologic side effects consisted predominantly of nausea, vomiting, and mucositis. One patient had transient cerebellar dysfunction. Recovery of blood counts occurred at a median of 24 days. The median time to CR was 38 days. As this regimen is highly effective in relapsed or refractory ALL, its use during earlier stage of the disease is warranted.

Similar articles

Substances

MeSH terms

Publication Types

LinkOut - more resources